The role of osteoclasts in breast cancer bone metastasis

Journal of Bone Oncology

Volumn 5, Issue 3, 2016, Pages 93-95

  Le Pape, François ^a,b   Vargas, Geoffrey ^a,b   Clézardin, Philippe ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Bone resorption; miRNA; OPG; PTHrP; RANK; RANKL

Indexed keywords

TUMOR MARKER;

ARTICLE; BONE DEFECT; BONE METASTASIS; BREAST CANCER; BREAST CANCER CELL LINE; HUMAN; METASTASIS POTENTIAL; MOLECULAR PATHOLOGY; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84963626018     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2016.02.008     Document Type: Article

References (20)

1. [1] Weigelt, B., Peterse, J.L., van't Veer, L.J., Breast cancer metastasis: markers and models. Nat. Rev. Cancer 5:8 (2005), 591–602.
2. [2] Edwards, J.R., Mundy, G.R., Advances in osteoclast biology: old findings and new insights from mouse models. Nat. Rev. Rheumatol. 7:4 (2011), 235–243.
3. [3] Boyce, B.F., Xing, L., Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys. 473:2 (2008), 139–146.
4. [4] Lam, J., Takeshita, S., Barker, J.E., Kanagawa, O., Ross, F.P., Teitelbaum, S.L., TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106:12 (2000), 1481–1488.
5. [5] F.P. Ross, Osteoclast Biology and Bone Resorption, Prim. Metab. Bone Dis. Disord. Miner. Metab., 2013, pp. 23–33.
6. [6] Cappariello, A., Maurizi, A., Veeriah, V., Teti, A., The Great Beauty of the osteoclast. Arch. Biochem. Biophys. 558 (2014), 70–78.
7. [7] A.L. Boskey, P. Gehron Robey, The composition of bone, Prim. Metab. Bone Dis. Disord. Miner. Metab., 2013, pp. 49–58.
8. [8] Clézardin, P., Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res., 13(2), 2011, 207.
9. [9] Weilbaecher, K.N., Guise, T.A., McCauley, L.K., Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11:6 (2011), 411–425.
10. [10] Mundy, G.R., Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2:8 (2002), 584–593.
11. [11] Nelson, J., Bagnato, A., Battistini, B., Nisen, P., The endothelin axis: emerging role in cancer. Nat. Rev. Cancer 3 (2003), 110–116.
12. [12] Fradet, A., Sorel, H., Bouazza, L., Goehrig, D., Dépalle, B., Bellahcène, A., Castronovo, V., Follet, H., Descotes, F., Aubin, J.E., Clézardin, P., Bonnelye, E., Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. Cancer Res. 71:17 (2011), 5728–5738.
13. [13] Clément-Demange, L., Clézardin, P., Emerging therapies in bone metastasis. Curr. Opin. Pharmacol. 22 (2015), 79–86.
14. [14] Croset, M., Kan, C., Clézardin, P., Tumour-derived miRNAs and bone metastasis. Bone Rep., 4, 2015, 688.
15. [15] Ell, B., Mercatali, L., Ibrahim, T., Campbell, N., Schwarzenbach, H., Pantel, K., Amadori, D., Kang, Y., Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell 24:4 (2013), 542–556.
16. [16] Sugatani, T., Vacher, J., Hruska, K.A., Dc, W., Sugatani, T., Vacher, J., Hruska, K.A., A microRNA expression signature of osteoclastogenesis. Blood 117:13 (2012), 3648–3657.
17. [17] Lee, D.Y., Deng, Z., Wang, C.-H., Yang, B.B., MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc. Natl. Acad. Sci. USA 104:51 (2007), 20350–20355.
18. [18] O'Day, E., Lal, A., MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res., 12(2), 2010, 201.
19. [19] Buijs, J.T., Stayrook, K.R., Guise, T.A., The role of TGF-β in bone metastasis: novel therapeutic perspectives. Bone Rep. 1:6 (2012), 1–10.
20. [20] Sanders, J.L., Chattopadhyay, N., Kifor, O., Yamaguchi, T., Butters, R.R., Brown, E.M., Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology 141:12 (2000), 4357–4364.